TransMedics Group, Inc.
TMDX
$87.72
-$0.52-0.59%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 82.74% | 109.09% | 137.47% | 149.23% | 158.53% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 82.74% | 109.09% | 137.47% | 149.23% | 158.53% |
| Cost of Revenue | 105.03% | 151.11% | 201.48% | 200.09% | 210.53% |
| Gross Profit | 70.08% | 87.58% | 108.78% | 126.14% | 136.08% |
| SG&A Expenses | 43.44% | 44.56% | 53.11% | 59.04% | 68.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 67.56% | 81.35% | 98.53% | 96.75% | 93.07% |
| Operating Income | 7,631.13% | 407.01% | 285.46% | 162.07% | 101.54% |
| Income Before Tax | 234.15% | 187.70% | 108.36% | 58.73% | 26.25% |
| Income Tax Expenses | 119.23% | 101.10% | -2,271.43% | -2,153.52% | -2,589.39% |
| Earnings from Continuing Operations | 241.70% | 191.22% | 116.87% | 63.98% | 30.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 241.70% | 191.22% | 116.87% | 63.98% | 30.92% |
| EBIT | 7,631.13% | 407.01% | 285.46% | 162.07% | 101.54% |
| EBITDA | 560.98% | 1,114.64% | 509.14% | 231.60% | 130.98% |
| EPS Basic | 239.32% | 189.85% | 114.87% | 66.86% | 38.29% |
| Normalized Basic EPS | 1,306.25% | 437.77% | 270.93% | 157.87% | 106.28% |
| EPS Diluted | 230.87% | 184.64% | 105.83% | 63.37% | 37.52% |
| Normalized Diluted EPS | 1,385.08% | 418.71% | 261.50% | 154.75% | 105.61% |
| Average Basic Shares Outstanding | 2.19% | 1.96% | 3.22% | 6.60% | 10.06% |
| Average Diluted Shares Outstanding | 7.04% | 8.04% | 7.65% | 9.42% | 11.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |